Al technical title is built by PatSnap Al team. It summarizes the technical point description of the patent document.
A compound, n-b- technology, applied in the field of DPP-4-related diseases, dipeptidyl peptidase IV (DPP-4) inhibitor compounds, can solve the problem of GLP-1 inactivation and so on
Active Publication Date: 2015-08-05
NANJING HUAWE MEDICINE TECH DEV
View PDF4 Cites 0 Cited by
Summary
Abstract
Description
Claims
Application Information
AI Technical Summary
This helps you quickly interpret patents by identifying the three key elements:
Problems solved by technology
Method used
Benefits of technology
Problems solved by technology
However, DPP-4 can rapidly cleave proline or alanine at the second position of the N-terminal of the GLP-1 peptide chain in vivo, resulting in the inactivation of GLP-1
Method used
the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more
Image
Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
Click on the blue label to locate the original text in one second.
Reading with bidirectional positioning of images and text.
Smart Image
Examples
Experimental program
Comparison scheme
Effect test
Embodiment 1
[0073]
[0074] experiment procedure:
[0075] first step:
[0076] Method A
[0077] Weigh Boc-(R)-3-amino-4-(2,4,5-trifluorophenyl)butanoic acid (1.0g, 3.0mmol), anhydrous piperazine (0.26g, 3.0mmol), HBTU ( 2.27g, 6.0mmol) was added into a 100ml round bottom flask, dissolved in 20ml of DMF, then DIEA (0.78g, 6.0mmol) was added to the reaction solution, and stirred at room temperature for 1.5 hours. TLC detection (petroleum ether: ethyl acetate = 4:1), the reaction was completed, the reaction solution was added to 10 times the amount of water, a white solid was precipitated, filtered, the filter cake was washed with water, and the obtained solid was dried.
[0078] Method B
[0079] Weigh Boc-(R)-3-amino-4-(2,4,5-trifluorophenyl)butanoic acid (1.0g, 3.0mmol), anhydrous piperazine (0.26g, 3.0mmol), DCC ( 6.0mmol) and HoBt (6.0mmol) were added to a 100ml round bottom flask, dissolved with 20ml DMF, then DIEA (12.0mmol) was added to the reaction solution, and stirred at ...
Embodiment 2
[0085] Chemical reaction formula:
[0086]
[0087] Experimental process: The specific experimental process of compound 2 is similar to that of Example 1, refer to Example 1.
the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more
PUM
Login to view more
Abstract
The invention provides a novel dipeptidyl peptidase IV (DPP-4) inhibitor compound as shown in Formula (I) as shown in the specification. The compound, optical isomers, pharmaceutically acceptable inorganic or organic salt, crystal forms, hydrates or solvates of the compound can be used for treating diabetes, particularly non-insulin dependent diabetes, and other diseases related to DPP-4. Definitions of substituents in the general formula (I) are the same as those in the specification.
Description
technical field [0001] The invention belongs to the field of organic synthesis, and specifically relates to a novel dipeptidyl peptidase IV (DPP-4) inhibitor compound and its application for treating and preventing diabetes and other diseases related to DPP-4. Background technique [0002] Diabetes is a chronic metabolic disease caused by various pathogenic factors such as genetic factors, immune dysfunction, microbial infection and its toxins, free radical toxins, and mental factors. Clinically, it is characterized by hyperglycemia. It can be divided into type 1 diabetes (insulin-dependent), type 2 diabetes (non-insulin-dependent), gestational diabetes and other special types of diabetes. Type 2 diabetes accounts for approximately 95% of diabetic patients. [0003] At present, the main oral hypoglycemic drugs are: sulfonylureas (SU), biguanides, α-glucosidase inhibitors, non-sulfonylurea insulin secretory drugs and insulin sensitizers: thiazolidinediones. These drugs are ...
Claims
the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more
Application Information
Patent Timeline
Application Date:The date an application was filed.
Publication Date:The date a patent or application was officially published.
First Publication Date:The earliest publication date of a patent with the same application number.
Issue Date:Publication date of the patent grant document.
PCT Entry Date:The Entry date of PCT National Phase.
Estimated Expiry Date:The statutory expiry date of a patent right according to the Patent Law, and it is the longest term of protection that the patent right can achieve without the termination of the patent right due to other reasons(Term extension factor has been taken into account ).
Invalid Date:Actual expiry date is based on effective date or publication date of legal transaction data of invalid patent.
Login to view more 
Login to view more